JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Evaluation of the frequency of hepatitis b virus reactivation and the importance of hepatitis b prophylaxis in hematology patients receiving immunosuppressive therapy: a single-center study
Abstract
Aims: The aim of this study was to evaluate the rate of hepatitis B virus reactivation (HBVr) in hematology patients receiving immunosuppressive therapy in our center and the clinical characteristics of patients with HBVr. We will also investigate the importance of effective prevention of this potentially life-threatening event and management of hepatitis B virus (HBV) prophylaxis.
Methods: In this study, hepatitis B prophylaxis and its effects on patients over 18 years of age receiving immunosuppressive therapy in the hematology clinic were analyzed. 122 patients were included in the study. The HBV markers of the patients were determined by the chemiluminescence method. In the study, HbsAg(+) and isolated antiHbc IgG-positive patients received prophylactic antiviral treatment. The differential diagnosis of HBV reactivation and the criteria determined to define HBV reactivation were performed. Clinical characteristics and descriptive information of patients receiving HBV prophylaxis were analyzed using SPSS 25.0.
Results: The median age of 122 patients (59.8% male) was 58 years. It was determined that five HbsAg-positive patients had no prior follow-up and did not receive antiviral treatment. 117 patients had isolated anti-HBc IgG positivity. The median duration of prophylaxis was 15 (9- 21.25) months, and the total follow-up period was 19.5 (11.75- 30.25) months. 81.1% of the patients received regular HBV prophylaxis treatment; 59% of them received entecavir, and the rest received tenofovir disoproxil. Bone marrow transplantation was performed in 25 patients. HBV reactivation was detected in only 4 patients (3.3%); one of these patients had received allogeneic and one autologous bone marrow transplantation; and three patients had received chemoimmunotherapy including Rituximab. The diagnoses of the patients with HBVr were acute myeloid leukemia, lymphoma, and chronic lymphocytic leukemia. During the follow-up period, 29 patients (23.8%) died due to their primary disease, but there were no deaths due to HBV reactivation.
Conclusion: The data obtained in this study show that effective hepatitis B prophylaxis treatment is successful in preventing HBV reactivation in hematology patients. HBVr was observed in four patients who did not take HBV prophylaxis medication regularly.

Keywords : Hematology, immunosuppressive therapy, hepatitis B, prophylaxis, reactivation

Download Article


1. Zannella A, Marignani M, Begini P. Hematological Malignancies andHBV reactivation risk: suggestions for clinical management. Viruses.2019;11(9):858-872.
2. Söğütçü N, Kaya S. Evaluation of Liver biopsy results in chronichepatitis b patients. Van Med J. 2020;27(4):403-406.
3. Riveiro-Barciela M, Gubern P, Roade L, et. al. An electronic alert systemincreases screening for hepatitis B and C and improves management ofpatients with haematological disorders. Sci Rep. 2020;10(1):3038-3045.
4. Buti M, Manzano ML, Morillas RM, et.al. Randomized prospectivestudy evaluating tenofovir disoproxil fumarate prophylaxis againsthepatitis B virus reactivation in anti- HBc-positive patients withrituximab-based regimens to treat hematologic malignancies: thepreblin study. Plos One. 2017;12(9):1-14.
5. Wang B, Mufti G, Agarwal K. Reactivation of hepatitis B virusinfection in patients with hematologic disorders. Haematologica.2019;104(3):435-443.
6. Ekinci O, Kara O, Demircioglu S, et. al. Evaluation of transfusiontransmitted infections and distribution of ABO and Rh blood groupsin donors in Eastern Turkey. Annals of Med Res. 2019;26(9):2088-2092.
7. Bozkurt I, Bektas A. Anti-TNF alfa kullanan hastalarda hepatit Breaktivasyonunun değerlendirilmesi. Dicle Med J. 2019;46(3):553-557.
8. Lampertico P, Agarwal K, Berg T. EASL 2017 clinical practiceguidelines on the management of hepatitis B virus infection. J Hepatol.2017;67(2):370-398.
9. Xu MH, Chen M, Cai Y, Jia YH. Clinical outcomes of low-doseleflunomide for rheumatoid arthritis complicated with Hepatitis B viruscarriage and safety observation. Pak J Med Sci. 2015;31(2):320-324.
10. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis Bvirus (HBV) reactivation in lymphoproliferative diseases: metaanalysisand examination of FDA safety reports. Ann Oncol. 2011;22(5):1170-1180.
11. Kusumoto S, Arcaini L, Hong X, et al. Risk of HBV reactivation inpatients with B-cell Lymphomas receiving obinutuzumab or rituximabimmunochemotherapy. Blood. 2019;133(2):137-146.
12. Huang HH, Hsiao FY, Chen HM, Wang CY, Ko BS. Antiviralprophylaxis for hepatitis B carriers improves the prognosis of diffuselarge B-cell lymphoma in Taiwan-a population-based study. BritishSoci Haematol. 2021;192(1):110-118. doi: 10.1111/bjh.17142
13. Loglio A, Vigano M, Grossi G, et al. Lamivudine prophylaxis preventshepatitis B virus reactivation in anti-HBc positive patients under rituximabfor non-Hodgkin lymphoma. Dig Liver Dis. 2019;51(3):419-424.
14. Papadopoulosa N, Deutschc M, Manolakopoulosc S, et al. Efficacy ofprophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.Europ J Gastroenterol & Hepatol. 2017;29(1):56-60.
15. Wu Y, Huang H, Luo Y. Management of hepatitis B virus inallogeneic hematopoietic stem cell transplantation. Front Immunol.2021;11:610500 doi: 10.3389/fimmu.2020.610500.
16. Smalls DJ, Kiger RE, Norris LB, Bennett CL, Love BL. Hepatitis Bvirus reactivation: risk factors and current management strategies.Pharmacother. 2019;39(12):1190-1203.
17. Nakamoto S, Kanda T, Nakaseko C, et al. Reactivation of hepatitis Bvirus in hematopoietic stem cell transplant recipients in Japan: efficacyof nucleos(t)ide analogues for prevention and treatment. Int J Mol Sci.2014;15(11):21455-21467.
Article available in :
Volume 1, Issue 4, 2023
Page : 83-87
https://doi.org/10.51271/JCHOR-0019
Article Information
Received : 03 Kas 2023
Accepted : 26 Kas 2023
Published : 30 Kas 2023
Corresponding Author :

Ali Doğan: Responsible Author

[email protected]
Citation : Doğan A, Ekinci Ö, Yıldırım Doğan N, et al. Evaluation of the frequency of hepatitis B virus reactivation and the importance of hepatitis B prophylaxis in hematology patients receiving immunosuppressive therapy: a single-center study. J Curr Hematol Oncol Res. 2023;1(4):83-87.

Read: 312
Cited: 0
Download : 208
_Footer